{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:01:26Z","timestamp":1788472886806,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Positron emission tomography (PET) is increasingly used in neuro-oncology. However, little is known about its application across European institutions and reasons for variable implementation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between June and August 2024, members of the European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) completed a cross-sectional online survey on PET use in neuro-oncological practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, 103 replies from 20 countries were received. A PET facility was available at 96\/103 (93.2%) sites, of whom 74 (77.1%) performed PET in patients with brain tumours. Reasons for not performing PET included limited availability of tracers (14\/29, 48.3%), high cost (11\/29, 37.9%), and PET perceived unnecessary (8\/29, 27.6%). Of sites performing PET, 69\/74 (93.2%) reported use in glioma, 58\/74 (78.4%) in brain metastasis, 52\/74 (70.3%) in meningioma, and 46\/74 (62.2%) in CNS lymphoma. Amino acid PET was performed at 62\/71 centres (87.3%; 3 not reported [n.r.]), most frequently in glioma (58\/59, 98.3%, 3 n.r.) and for differentiation of treatment-related changes from tumour progression (58\/59, 98.3%). Somatostatin receptor (SSTR) PET was performed at 50\/68 sites (73.5%, 6 n.r.), mainly in meningioma (48\/49, 98.0%), for patient selection before radioligand therapy (41\/49, 83.7%) and for radiotherapy target volume definition (33\/49, 67.3%). Unrestricted coverage by statutory health insurance was reported by 46\/59 (78.0%) centres for amino acid PET and 33\/49 (67.3%) for SSTR PET.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>PET use in neuro-oncology is variable across EORTC-BTG sites. Generation of evidence in clinical trials and surveys including non-academic institutions are needed to guide implementation in clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07366-0","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:53:01Z","timestamp":1749019981000},"page":"4627-4638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Availability and use of PET in patients with brain tumours \u2013 a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-3874","authenticated-orcid":false,"given":"Maximilian J.","family":"Mair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Belting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petter","family":"Brandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martinus P. G.","family":"Broen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cicone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Daisne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ducray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Furtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asgeir S.","family":"Jakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Niyazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pellerino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Rasschaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Razis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelleke","family":"Tolboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Verger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0953-7624","authenticated-orcid":false,"given":"Nathalie L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"7366_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18:170\u201386.","journal-title":"Nat Rev Clin Oncol"},{"key":"7366_CR2","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","volume":"23","author":"R Goldbrunner","year":"2021","unstructured":"Goldbrunner R, Stavrinou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro-Oncol. 2021;23:1821\u201334.","journal-title":"Neuro-Oncol"},{"key":"7366_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","volume":"32","author":"E Le Rhun","year":"2021","unstructured":"Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, et al. EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol. 2021;32:1332\u201347.","journal-title":"Ann Oncol"},{"key":"7366_CR4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7366_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","volume":"46","author":"I Law","year":"2019","unstructured":"Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM\/EANO\/RANO practice guidelines\/snmmi procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7366_CR6","doi-asserted-by":"crossref","unstructured":"Verger A, Tolboom N, Cicone F, Chang SM, Furtner J, Galldiks N, et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standard for PET imaging of brain metastases: version 1.0. Eur J Nucl Med Mol Imaging. 2025;52:1822\u201339.","DOI":"10.1007\/s00259-024-07038-5"},{"key":"7366_CR7","doi-asserted-by":"crossref","unstructured":"Albert NL, Preusser M, Traub-Weidinger T, Tolboom N, Law I, Palmer JD, et al. Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0. Eur J Nucl Med Mol Imaging. 2024;51:3662\u201379.","DOI":"10.1007\/s00259-024-06783-x"},{"key":"7366_CR8","doi-asserted-by":"crossref","unstructured":"Galldiks N, Lohmann P, Aboian M, Barajas RF, Breen WG, Ivanidze J, et al. Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 2025. [in press]","DOI":"10.1093\/neuonc\/noaf170"},{"key":"7366_CR9","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024;25:e29\u201341.","journal-title":"Lancet Oncol"},{"key":"7366_CR10","doi-asserted-by":"crossref","unstructured":"Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, et al. Response assessment of brain metastases based on amino acid PET imaging: PET RANO BM 1.0 criteria. Nat Med.\u00a02025;31:1424\u201330.","DOI":"10.1038\/s41591-025-03633-7"},{"key":"7366_CR11","unstructured":"Publications Office of the European Union. EuroVoc: Multilingual Thesaurus of the European Union, version 4.21. [Internet]. 2025. Available from: https:\/\/eur-lex.europa.eu\/browse\/eurovoc.html"},{"key":"7366_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1093\/nop\/npab027","volume":"8","author":"EE Parent","year":"2021","unstructured":"Parent EE, Johnson DR, Gleason T, Villanueva-Meyer JE. Neuro-Oncology practice clinical debate: FDG PET to differentiate glioblastoma recurrence from treatment-related changes. Neuro-Oncol Pract. 2021;8:518\u201325.","journal-title":"Neuro-Oncol Pract"},{"key":"7366_CR13","unstructured":"Telix Pharmaceuticals Ltd. Telix Provides Regulatory Update on TLX101-CDx. 2025 Apr 28 [cited 2025 May 1]; Available from: https:\/\/ir.telixpharma.com\/static-files\/e40a4bf3-7398-4dbd-82eb-feb10e9295fc"},{"key":"7366_CR14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/neuonc\/not002","volume":"15","author":"DH Pafundi","year":"2013","unstructured":"Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro-Oncol. 2013;15:1058\u201367.","journal-title":"Neuro-Oncol"},{"key":"7366_CR15","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1038\/s41467-023-39731-8","volume":"14","author":"M Harat","year":"2023","unstructured":"Harat M, Rakowska J, Harat M, Szylberg T, Furtak J, Miechowicz I, et al. Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma. Nat Commun. 2023;14:4572.","journal-title":"Nat Commun"},{"key":"7366_CR16","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.wneu.2015.07.067","volume":"84","author":"J Gempt","year":"2015","unstructured":"Gempt J, Bette S, Buchmann N, Ryang Y-M, F\u00f6rschler A, Pyka T, et al. Volumetric analysis of F-18-FET-PET imaging for brain metastases. World Neurosurg. 2015;84:1790\u20137.","journal-title":"World Neurosurg"},{"key":"7366_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2967\/jnumed.114.149120","volume":"56","author":"W Rachinger","year":"2015","unstructured":"Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, P\u00f6schl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56:347\u201353.","journal-title":"J Nucl Med"},{"key":"7366_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11060-022-04011-w","volume":"158","author":"WG Breen","year":"2022","unstructured":"Breen WG, Youland RS, Giri S, Jacobson SB, Pafundi DH, Brown PD, et al. Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma. J Neurooncol. 2022;158:323\u201330.","journal-title":"J Neurooncol"},{"key":"7366_CR19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ijrobp.2021.03.032","volume":"110","author":"NN Laack","year":"2021","unstructured":"Laack NN, Pafundi D, Anderson SK, Kaufmann T, Lowe V, Hunt C, et al. Initial results of a phase 2 trial of 18F-DOPA PET-Guided Dose-Escalated radiation therapy for glioblastoma. Int J Radiat Oncol. 2021;110:1383\u201395.","journal-title":"Int J Radiat Oncol"},{"key":"7366_CR20","first-page":"242119","volume":"65","author":"A-L Grosu","year":"2024","unstructured":"Grosu A-L, Weber W, Graf E, Mix M, Wiehle R, Nestle U, et al. GLIAA: FET-PET- vs. MRI-based re-irradiation in recurrent glioblastoma. A prospective randomized trial. J Nucl Med. 2024;65:242119.","journal-title":"J Nucl Med"},{"key":"7366_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:1285\u201395.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7366_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/noae209","volume":"27","author":"R Rahman","year":"2025","unstructured":"Rahman R, Preusser M, Tsien C, Le Rhun E, Sulman EP, Wen PY, et al. Point\/Counterpoint: the role of reirradiation in recurrent glioblastoma. Neuro-Oncol. 2025;27:7\u201312.","journal-title":"Neuro-Oncol"},{"key":"7366_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","volume":"25","author":"M Preusser","year":"2024","unstructured":"Preusser M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, et al. Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. Trials. 2024;25:366.","journal-title":"Trials"},{"key":"7366_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.2967\/jnumed.123.266687","volume":"65","author":"J Rosen","year":"2024","unstructured":"Rosen J, Werner J-M, Ceccon GS, Rosen EK, Wollring MM, Stetter I, et al. MRI and 18 F-FET PET for multimodal treatment monitoring in patients with brain metastases: A Cost-Effectiveness analysis. J Nucl Med. 2024;65:838\u201344.","journal-title":"J Nucl Med"},{"key":"7366_CR25","first-page":"1677","volume":"63","author":"J Rosen","year":"2022","unstructured":"Rosen J, Ceccon G, Bauer EK, Werner J-M, Tscherpel C, Dunkl V, et al. Cost effectiveness of 18F-FET PET for early treatment response assessment in glioma patients after adjuvant Temozolomide chemotherapy. J Nucl Med Off Publ Soc Nucl Med. 2022;63:1677\u201382.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"7366_CR26","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","volume":"25","author":"NL Albert","year":"2024","unstructured":"Albert NL, Le Rhun E, Minniti G, Mair MJ, Galldiks N, Tolboom N, et al. Translating the theranostic concept to neuro-oncology: disrupting barriers. Lancet Oncol. 2024;25:e441\u201351.","journal-title":"Lancet Oncol"},{"key":"7366_CR27","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1093\/neuonc\/noae069","volume":"26","author":"MJ Mair","year":"2024","unstructured":"Mair MJ, Tabouret E, Johnson DR, Sulman EP, Wen PY, Preusser M, et al. Radioligand therapies in meningioma: evidence and future directions. Neuro-Oncol. 2024;26:S215\u201328.","journal-title":"Neuro-Oncol"},{"key":"7366_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"7366_CR29","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"7366_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","volume":"17","author":"C Kratochwil","year":"2015","unstructured":"Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313\u20138.","journal-title":"Mol Imaging Biol"},{"key":"7366_CR31","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1093\/neuonc\/now188.059","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Sch\u00fcller U, Rushing E, Nicolas G, Sch\u00e4fer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro-Oncol. 2016;18:1538\u201347.","journal-title":"Neuro-Oncol"},{"key":"7366_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijrobp.2005.12.006","volume":"65","author":"S Milker-Zabel","year":"2006","unstructured":"Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol. 2006;65:222\u20137.","journal-title":"Int J Radiat Oncol"},{"key":"7366_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00259-009-1270-2","volume":"37","author":"F Nyuyki","year":"2010","unstructured":"Nyuyki F, Plotkin M, Graf R, Michel R, Steffen I, Denecke T, et al. Potential impact of 68Ga-DOTATOC PET\/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging. 2010;37:310\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07366-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07366-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07366-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:36:23Z","timestamp":1759394183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07366-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7366"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07366-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as this study did not involve human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable as this study did not involve human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable as this study did not involve human or animal subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MJM has received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre.PL has received honoraria for lectures from Blue Earth Diagnostics, and for advisory board participation from Servier.NG has received honoraria for lectures from Blue Earth Diagnostics, for advisory board participation from Telix Pharmaceuticals and Servier, and for consultancy services from Telix Pharmaceuticals.PB has received honoraria for lectures, consultation or advisory board participation from Servier, \u201cEkspertpanelet\u201d and \u201cMoloklinikken\u201d.JFD received honoraria for lectures from Varian and Ion Beam Applications, and for advisory board participation from Servier.FE has received honoraria and travel support from ZAP Surgical Systems, Inc., and Accuray, Inc., and acknowledges research funding from the German Cancer Aid and Accuray, Inc., all unrelated to the submitted work.JF has received honoraria for lectures, consultation or advisory board participation from Novartis, Seagen, Sanova, Servier.MN received speaker honoraria from Brainlab and Astra Zeneca.AP has received consultancy fees from Servier, unrelated to the submitted work.ER has received honoraria for advisory board from Gilead, Novartis, AstraZeneca and Servier survey and travel grants from Servier, AstraZeneca, Integris, BMS, Roche, Pfizer, Gilead.MS has received consultancy fees from Bracco (paid to institution) and speaker fees from the European School of Radiology (paid to institution).NT has received honoraria for advisory board participation and consultancy services from Telix Pharmaceuticals and receives in kind research support from Curium Pharma.AV has received honoraria for lectures and advisory board participation from Curium, Eisai, General Electrics and Novartis.ELR has received research grants from Bristol Meyers Squibb (BMS), and honoraria for lectures or advisory board participation or consulting from Astra Zeneca, Daiichi, Bayer, Biodexa\/Sitoxi, Janssen, Leo Pharma, Pfizer, Pierre Fabre, Roche, Seattle Genetics and Servier.GM has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Brainlab, Accuray, Servier, Astra-Zeneca, Novocure, Pfizer.MW has received research grants from Novartis, Quercis and Versameb, and honoraria for lectures or advisory board participation or consulting from Anheart, Bayer, Curevac, Medac, Neurosense, Novartis, Novocure, Orbus, Pfizer, Philogen, Roche and Servier.\u00a0MP has received honoraria for lectures, consultation or advisory board participation from Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CNC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Boehringer Ingelheim, Telix, Medscape, OncLive, Nerviano Medical Sciences.NLA has received honoraria for lectures, consultation or advisory board participation from ABX, Advanced Accelerator Applications, Carthera, ITM, Medsir, Novartis, OncLive, Servier and Telix Pharmaceuticals, and research funding from Novocure and Telix Pharmaceuticals.All other authors declare that they have no conflict of interest related to the present study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}